Inactive Instrument

Highlights Aviragen Therapeutics Inc Nasdaq

Equities

US0537611024

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

Vaxart, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 14	CI
North American Morning Briefing : Stock Futures -2-	Feb. 01	DJ
Vaxart Secures $9.3 Million Award for Phase 2b COVID-19 Pill Study	Jan. 19	MT
Vaxart, Inc. Announces Last Subject Dosed in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating Mothers	Dec. 21	CI
Vaxart, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 02	CI
Earnings Flash (VXRT) VAXART Posts Q3 Revenue $2.1M	Nov. 02	MT
Vaxart Doses First Subject in Phase 1 Trial of its Norovirus Vaccine Candidate in Lactating Mothers	Nov. 02	CI
Vaxart Announces Topline Data from the Phase 2 Challenge Study of Its Monovalent Norovirus Vaccine Candidate	23-09-06	CI
Vaxart, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-03	CI
Earnings Flash (VXRT) VAXART Reports Q2 Revenue $1.4M, vs. Street Est of $0.08M	23-08-03	MT
Vaxart, Inc. Announces Positive Preliminary Topline Data from Dose-Ranging Phase 2 Study of its Bivalent Norovirus Vaccine Candidate	23-07-10	CI
Vaxart, Inc. Announces Last Subject Dosed in Phase 2 Trial of Its Bivalent Norovirus Candidate, and All Subjects Challenge Study of Monovalent Norovirus Candidate	23-06-06	CI
Vaxart, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-04	CI
Earnings Flash (VXRT) VAXART Posts Q1 Revenue $675,000, vs. Street Est of $0.8M	23-05-04	MT
Inspirit Energy reports progress on Inspirit Charger	23-03-16	AN
Inspirit Energy reports progress on Inspirit Charger	23-03-16	AN
North American Morning Briefing : Futures Deep in -3-	23-03-15	DJ
Vaxart, Inc. Doses First Subject in the Phase 2 Clinical Trial of Its Bivalent Norovirus Candidate	23-02-14	CI
Vaxart, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-08	CI
Vaxart, Inc. Announces Positive Top-line Phase II Clinical Study Data Demonstrating Safety and Immunogenicity of Its Wuhan S-Only COVID-19 Pill Vaccine Candidate	22-09-01	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Aviragen Therapeutics Inc Nasdaq

Equities

US0537611024

Highlights

Filters